{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:26:20Z","timestamp":1788452780595,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10096-025-05107-7","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:45:37Z","timestamp":1742229937000},"page":"1335-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftazidime-avibactam use in hematology patients: single-center experience"],"prefix":"10.1007","volume":"44","author":[{"given":"Aysun","family":"Halacoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Koroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"3","key":"5107_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","volume":"46","author":"JL Liscio","year":"2015","unstructured":"Liscio JL, Mahoney MV, Hirsch EB (2015) Ceftolozane\/tazobactam and Ceftazidime\/avibactam: two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents 46(3):266\u2013271. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.05.003","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"5107_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","volume":"35","author":"EJ Zasowski","year":"2015","unstructured":"Zasowski EJ, Rybak JM, Rybak MJ (2015) The \u03b2-Lactams strike back: ceftazidime-avibactam. Pharmacotherapy 35(8):755\u2013770. https:\/\/doi.org\/10.1002\/phar.1622","journal-title":"Pharmacotherapy"},{"key":"5107_CR3","doi-asserted-by":"publisher","unstructured":"Shirley M (2018) Ceftazidime-Avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs 78(6):675\u201392. https:\/\/doi.org\/10.1007\/s40265-018-0902-x","DOI":"10.1007\/s40265-018-0902-x"},{"issue":"3","key":"5107_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, WHO Pathogens Priority List Working Group et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"5107_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cid\/ciu052","volume":"58","author":"MJ Satlin","year":"2014","unstructured":"Satlin MJ, Jenkins SG, Walsh TJ (2014) The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 58(9):1274\u20131283. https:\/\/doi.org\/10.1093\/cid\/ciu052","journal-title":"Clin Infect Dis"},{"key":"5107_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/IDR.S396428","volume":"16","author":"X Wei","year":"2023","unstructured":"Wei X, Li L, Li M, Liang H, He Y et al (2023) Risk factors and outcomes of patients with Carbapenem-Resistant Pseudomonas aeruginosa bloodstream infection. Infect Drug Resist 16:337\u2013346. https:\/\/doi.org\/10.2147\/IDR.S396428","journal-title":"Infect Drug Resist"},{"issue":"7","key":"5107_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"7","key":"5107_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"KD Khoury","year":"2022","unstructured":"Khoury KD, Solary E, Abla O, Akkari Y, Alaggio R et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"6","key":"5107_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16(6):661\u2013673. https:\/\/doi.org\/10.1016\/S1473-3099(16)30004-4","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"5107_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"3","key":"5107_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/antibiotics11030321","volume":"11","author":"M Di Pietrantonio","year":"2022","unstructured":"Di Pietrantonio M, Brescini L, Candi J, Gianluca M, Pallotta F et al (2022) Ceftazidime-avibactam for the treatment of multidrug-resistant pathogens: a retrospective, single center study. Antibiotics 11(3):321. https:\/\/doi.org\/10.3390\/antibiotics11030321","journal-title":"Antibiotics"},{"issue":"3","key":"5107_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","volume":"12","author":"A Soriano","year":"2023","unstructured":"Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G et al (2023) The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study. Infect Dis Ther 12(3):891\u2013917. https:\/\/doi.org\/10.1007\/s40121-023-00762-9","journal-title":"Infect Dis Ther"},{"issue":"10","key":"5107_CR13","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1080\/10428194.2016.1193859","volume":"57","author":"TM Baker","year":"2016","unstructured":"Baker TM, Satlin MJ (2016) The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leuk Lymphoma 57(10):2245\u20132258. https:\/\/doi.org\/10.1080\/10428194.2016.1193859","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"5107_CR14","doi-asserted-by":"publisher","first-page":"106335","DOI":"10.1016\/j.ijantimicag.2021.106335","volume":"57","author":"D Clerici","year":"2021","unstructured":"Clerici D, Oltolini C, Greco R, Ripa M, Giglio F et al (2021) The place of ceftazidime\/avibactam and ceftolozane\/tazobactam for therapy of haematological patients with febrile neutropenia. Int J Antimicrob Agents 57(6):106335. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106335","journal-title":"Int J Antimicrob Agents"},{"key":"5107_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","volume":"59","author":"JJ Cast\u00f3n","year":"2017","unstructured":"Cast\u00f3n JJ, Lacort-Peralta I, Mart\u00edn-D\u00e1vila P, Loeches B, Tabares S et al (2017) Clinical efficacy of Ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 59:118\u2013123. https:\/\/doi.org\/10.1016\/j.ijid.2017.03.021","journal-title":"Int J Infect Dis"},{"issue":"6","key":"5107_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkt002","volume":"68","author":"S Schelenz","year":"2013","unstructured":"Schelenz S, Nwaka D, Hunter PR (2013) Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of Ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother 68(6):1431\u20131438. https:\/\/doi.org\/10.1093\/jac\/dkt002","journal-title":"J Antimicrob Chemother"},{"issue":"45","key":"5107_CR17","doi-asserted-by":"publisher","first-page":"e1931","DOI":"10.1097\/MD.0000000000001931","volume":"94","author":"L Wang","year":"2015","unstructured":"Wang L, Wang Y, Fan X, Tang W, Hu J (2015) Prevalence of resistant gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study. Medicine 94(45):e1931. https:\/\/doi.org\/10.1097\/MD.0000000000001931","journal-title":"Medicine"},{"issue":"5","key":"5107_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","volume":"20","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y et al (2022) All-cause mortality rates in adults with carbapenem-resistant gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther 20(5):707\u2013719. https:\/\/doi.org\/10.1080\/14787210.2022.2020099","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5107_CR19","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.2147\/IDR.S419064","volume":"16","author":"F Yuan","year":"2023","unstructured":"Yuan F, Xiao W, Wang X, Fu Y, Wei X (2023) Clinical characteristics and prognosis of bloodstream infection with carbapenem-resistant Pseudomonas aeruginosa in patients with hematologic malignancies. Infect Drug Resist 16:4943\u20134952. https:\/\/doi.org\/10.2147\/IDR.S419064","journal-title":"Infect Drug Resist"},{"issue":"1","key":"5107_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4274\/tjh.2014.0010","volume":"33","author":"M Ozen","year":"2016","unstructured":"Ozen M, Y\u0131lmaz G, Coskun B, Topcuoglu P, Ozturk B et al (2016) A Quasi-Experimental study analyzing the effectiveness of portable High-Efficiency particulate absorption filters in preventing infections in hematology patients during construction. Turk J Haematol 33(1):41\u201347. https:\/\/doi.org\/10.4274\/tjh.2014.0010","journal-title":"Turk J Haematol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05107-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:57:21Z","timestamp":1748350641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05107-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["5107"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05107-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived because this was a retrospective analysis of routinely collected anonymized data. Consent was obtained from all patients during hospitalization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}